Blood Tests for Endocrine Conditions: Hormones, Glucose, and Metabolic Panels

Blood testing is the primary diagnostic instrument in endocrinology, enabling clinicians to detect hormonal imbalances, metabolic dysfunction, and gland-specific pathology before symptoms become severe or irreversible. The panels ordered span a wide range — from fasting glucose and glycated hemoglobin to pituitary hormone cascades and adrenal steroid profiles. Understanding what these tests measure, how results are interpreted, and when each panel applies helps clarify the diagnostic pathway that governs endocrine care across the United States. For a broader orientation to the field, the Endocrinology Authority index provides structured navigation across conditions, diagnostics, and treatments.

Definition and Scope

Endocrine blood testing refers to laboratory analysis of blood-borne substances — hormones, metabolites, binding proteins, and glucose — that reflect the output and feedback status of hormone-producing glands. The endocrine system comprises at least nine major glands, including the thyroid, adrenal glands, pituitary, parathyroid, pancreatic islets, and gonads, each secreting measurable analytes into systemic circulation.

The clinical scope of these tests is defined partly by regulatory oversight. In the United States, clinical laboratory testing falls under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS CLIA Program). Laboratories performing hormone assays must meet CLIA proficiency standards appropriate to the test complexity category. The Food and Drug Administration (FDA) regulates in vitro diagnostic (IVD) devices — including immunoassay analyzers used for thyroid-stimulating hormone (TSH), cortisol, and testosterone measurement — under 21 CFR Part 809 (FDA IVD Regulations).

The regulatory context for endocrinology covers how federal oversight shapes laboratory standards, reference ranges, and quality controls that affect diagnostic accuracy across endocrine specialties.

How It Works

Blood tests for endocrine conditions work through three principal measurement mechanisms:

  1. Immunoassay — The dominant method for hormone quantification. A labeled antibody binds selectively to the target analyte (e.g., TSH, LH, insulin, cortisol). Signal intensity correlates with analyte concentration. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescent immunoassay (CLIA-based) are the most common formats in hospital laboratories.

  2. Electrochemical and enzymatic assay — Used primarily for glucose and metabolite panels. A glucometer or automated analyzer uses glucose oxidase or hexokinase reactions to produce a measurable electrical or spectrophotometric signal proportional to glucose concentration in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).

  3. Mass spectrometry (LC-MS/MS) — Liquid chromatography–tandem mass spectrometry is the reference-standard method for steroid hormone panels, including testosterone, estradiol, DHEA-S, and aldosterone. The Endocrine Society endorses LC-MS/MS over immunoassay for testosterone measurement due to superior specificity at low concentrations (Endocrine Society Clinical Practice Guideline on Testosterone Therapy, 2018).

The feedback axis principle governs interpretation of most endocrine panels. Glands operate within hypothalamic-pituitary-peripheral gland axes; testing both the stimulating hormone (e.g., TSH) and the effector hormone (e.g., free T4) simultaneously distinguishes primary gland failure from central (pituitary or hypothalamic) dysfunction. A high TSH with low free T4 indicates primary hypothyroidism; a low TSH with low free T4 points to secondary (central) hypothyroidism — a clinically distinct and more serious condition explored further on the thyroid function tests page.

Common Scenarios

The following panels represent the highest-frequency diagnostic workups in outpatient endocrine practice:

Diabetes and glucose metabolism panels:
- Fasting plasma glucose (FPG) — Diagnostic threshold for diabetes is ≥126 mg/dL on two occasions, per American Diabetes Association Standards of Care 2024
- Hemoglobin A1c (HbA1c) — Reflects 90-day average glycemia; diagnostic cutoff ≥6.5%; see hemoglobin A1c and glucose monitoring for methodology detail
- Fasting insulin and C-peptide — Differentiates insulin resistance from beta-cell failure; covered further at insulin and C-peptide testing
- Oral glucose tolerance test (OGTT) — 75 g glucose load with plasma glucose measured at 0 and 120 minutes; gestational diabetes screen uses a 50 g or 100 g protocol

Thyroid panels:
- TSH, free T4, free T3
- Thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TgAb) for autoimmune differentiation
- Thyroglobulin (Tg) — Tumor marker used in differentiated thyroid cancer surveillance post-thyroidectomy

Adrenal panels:
- 8 AM serum cortisol and ACTH — Primary screen for adrenal insufficiency; an 8 AM cortisol below 3 mcg/dL is highly suggestive of insufficiency (Endocrine Society Adrenal Insufficiency Guidelines, 2016)
- 24-hour urine free cortisol (UFC) or late-night salivary cortisol — First-line screening for Cushing syndrome
- Plasma metanephrines — Biochemical screening for pheochromocytoma

Pituitary and reproductive panels:
- Prolactin, LH, FSH, IGF-1 (surrogate for growth hormone), GH stimulation testing
- Testosterone (total and free by LC-MS/MS) and sex hormone–binding globulin (SHBG)
- AMH (anti-Müllerian hormone) and androgen panels in polycystic ovary syndrome workup; see polycystic ovary syndrome for diagnostic criteria context

Decision Boundaries

Not every hormone test is appropriate in every clinical context. Three key boundaries govern appropriate test selection:

Confirmatory vs. screening tests: Screening tests carry high sensitivity but may generate false positives requiring confirmation. A positive 1 mg overnight dexamethasone suppression test (DST) — suppression failure defined as post-DST cortisol >1.8 mcg/dL — requires confirmation with UFC or late-night salivary cortisol before a Cushing syndrome diagnosis can be established, per Endocrine Society Cushing's Syndrome Guidelines.

Dynamic vs. static testing: Static tests (single-point hormone concentration) are often insufficient for pituitary assessment. Growth hormone deficiency in adults requires a stimulation test — typically insulin tolerance test (ITT) or glucagon stimulation test — because baseline GH levels cannot distinguish deficiency from normal physiologic suppression. Likewise, primary hyperaldosteronism requires a confirmatory fludrocortisone suppression test or salt infusion test after an elevated aldosterone-to-renin ratio (ARR) screen.

Preanalytical variables: Cortisol, growth hormone, LH, and FSH exhibit pulsatile secretion and diurnal variation. Cortisol is highest between 6–8 AM and lowest near midnight; samples drawn outside the appropriate window produce uninterpretable results. Biotin (vitamin B7) supplementation at doses above 5 mg/day can artifactually suppress or elevate immunoassay-based hormone values — a safety concern flagged by the FDA in a 2019 safety communication (FDA Biotin Interference Alert).

Interpreting results also requires reference range alignment: ranges vary by assay platform, patient sex, and reproductive status. The Endocrine Society and the College of American Pathologists (CAP) both publish guidance on harmonizing hormone assay standards across laboratories to reduce inter-laboratory variability, which can exceed 20% for testosterone immunoassays compared to LC-MS/MS reference methods.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)